Showing 3341-3350 of 7638 results for "".
- Five-Year Retrospective Study Shows 98.9 Percent Cure Rate for NMSC Patients Treated with Superficial Radiation Therapyhttps://practicaldermatology.com/news/five-year-retrospective-study-shows-989-percent-cure-rate-for-nmsc-patients-treated-with-superficial-radiation-therapy/2460013/Sensus Healthcare, Inc. shared topline results from a five-year retrospective study of non-melanoma skin cancer (NMSC) patients treated with Superficial Radiation Therapy (SRT). The study, which was conducted across four U.S. sites, showed a 98.9 percent cure rate among 516 male and female patients…
- SkinBioTherapeutics Names New Executive Directorhttps://practicaldermatology.com/news/skinbiotherapeutics-names-new-executive-director/2460012/Stuart Ashman is the new executive director of SkinBioTherapeutics. Mr. Ashman will succeed Professor Cath O’Neill as CEO after a period of transition. Ms. O’Neill will continue to drive the science and the ongoing commercial discussions she has initiated. He brings more than two decades of comme…
- Study Highlights Adverse Events Associated with Energy-Based Vaginal Rejuvenationhttps://practicaldermatology.com/news/study-highlights-adverse-events-associated-with-energy-based-vaginal-rejuvenation/2460010/Concerns from the federal Food and Drug Administration (FDA) sired the first assessment of adverse events related to device-based procedures marketed for ‘vaginal rejuvenation,’ and the new analysis of the Manufacturer and User Facility Device Experience (MAUDE) database identified a total of 45 di…
- FDA Approves Ortho Dermatologics' Duobrii for Treatment of Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-ortho-dermatologics-duobrii-for-treatment-of-plaque-psoriasis/2460009/The FDA has approved Ortho Dermatologics' New Drug Application for Duobrii (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, indicated for the topical treatment of plaque psoriasis in adults. Duobrii is the only topical lotion that contains a unique combination of halobetasol propionate…
- FDA Approves AbbVie's Skyrizi for Psoriasishttps://practicaldermatology.com/news/fda-approves-abbvies-skyrizi-for-psoriasis/2460007/Skyrizi™ (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor from AbbVie, is FDA approved for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. In clinical trials, Skyrizi produced high rates of durable skin clearance with 8…
- Brooke Shields Takes on New Role as Celebrity Spokesperson for SculpSure Body Contouringhttps://practicaldermatology.com/news/brooke-shields-take-on-new-role-as-celebrity-spokesperson-for-sculpsure-body-contouring/2460005/Actress, model, Broadway star, and author Brooke Shields will serve as national spokesperson for Hologic’s Cynosure's SculpSure body contouring laser treatment. As the face of SculpSure’s new “Be strong. Be sexy. Be confident.” campaign, Ms. Shields will inspire consumers to live confidently in a b…
- Fibrocell to Collaborate with Castle Creek Pharmaceuticals to Develop and Commercialize RDEB Gene Therapyhttps://practicaldermatology.com/news/fibrocell-to-collaborate-with-castle-creek-pharmaceuticals-to-develop-and-commercialize-rdeb-gene-therapy/2460004/Fibrocell Science, Inc. has entered into a collaboration agreement with Castle Creek Pharmaceuticals to develop and commercialize Fibrocell’s lead gene therapy candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a rare, life-threatening genetic disorder diagn…
- L'Oreal To Support Reconstruction of Notre Dame Cathedralhttps://practicaldermatology.com/news/loreal-to-support-reconstruction-of-notre-dame-cathedral/2460003/The Bettencourt Meyers family and the L’Oréal Group are making a joint donation of 100 million euros toward the “renaissance” of the Notre-Dame Cathedral, which they describe as a symbol of French heritage and common history. The L’Oréal group will also support fundraising among its 86,000 employ…
- Industry Vet Linda Esposito Named New CFO at Skyn ICELANDhttps://practicaldermatology.com/news/industry-vet-linda-esposito-named-new-cfo-at-skyn-iceland/2460002/Linda Esposito is the new Chief Financial Officer at Skyn ICELAND, a privately held New York-based skin care company. Ms. Esposito will report to Founder and Chief Executive Officer Sarah Kugelman and will oversee all financial aspects of the Company. "On behalf of Skyn ICELAND, I am very pleased…
- InMode Launches AccuTite, the Smallest RFAL Treatment for Face and Bodyhttps://practicaldermatology.com/news/inmode-launches-accutite-the-smallest-rfal-treatment-for-face-and-body/2460000/InMode Ltd. is introducing AccuTite, the smallest Radio-Frequency Assisted Lipolysis (RFAL) device for precision fat reduction or skin contraction in the face and body. With its sub-millimeter cannula, AccuTite enables focal RF contraction without excisional surgery. There is little or no visible …